QiagenQGEN
QGEN
About: Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
Employees: 5,800
0
Funds holding %
of 7,372 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
48% more call options, than puts
Call options by funds: $52.2M | Put options by funds: $35.2M
7% more repeat investments, than reductions
Existing positions increased: 116 | Existing positions reduced: 108
4% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 50
4% less capital invested
Capital invested by funds: $6.9B [Q3] → $6.6B (-$308M) [Q4]
2% less funds holding
Funds holding: 325 [Q3] → 319 (-6) [Q4]
2.58% less ownership
Funds ownership: 69.01% [Q3] → 66.43% (-2.58%) [Q4]
50% less funds holding in top 10
Funds holding in top 10: 6 [Q3] → 3 (-3) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$42
7%
upside
Avg. target
$46
18%
upside
High target
$49
26%
upside
3 analyst ratings
0 positive
0%
3 neutral
100%
0 negative
0%
Baird Catherine Schulte 0% 1-year accuracy 0 / 20 met price target | 7%upside $42 | Neutral Downgraded | 19 Feb 2025 |
UBS John Sourbeer 0% 1-year accuracy 0 / 1 met price target | 22%upside $48 | Neutral Maintained | 7 Feb 2025 |
Morgan Stanley Steve Beuchaw 0 / 0 met price target | 26%upside $49 | Equal-Weight Downgraded | 6 Jan 2025 |
Financial journalist opinion
Based on 6 articles about QGEN published over the past 30 days
Positive
Zacks Investment Research
1 week ago
Is it Worth Retaining QIAGEN Stock in Your Portfolio Now?
QGEN's robust expansion of its testing menu and potential in molecular diagnostics bode well for investors.
Positive
Zacks Investment Research
1 week ago
QGEN Stock Up on FDA Nod for Second QIAstat-Dx Gastrointestinal Panel
QIAGEN wins the FDA's clearance for the second QIAstat-Dx mini gastrointestinal panel.
Neutral
Business Wire
2 weeks ago
QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, further strengthening its syndromic testing portfolio in the United States. This marks QIAGEN's second FDA clearance of a QIAstat-Dx panel in 2025, and builds on the authorization of five panels for use on the QIAstat-Dx system within the last 10 mont.
Neutral
Business Wire
2 weeks ago
QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing
VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A. (EPA: BIM) for patent infringement, reinforcing its commitment to protecting the scientific advancements behind its proprietary QuantiFERON technology. The complaint, filed in the Local Division of the Court of First Instance of the Unified Patent Court (UPC) in Duesseldorf, Germany, concerns European Patent EP 2 276 883 B2. This.
Neutral
Seeking Alpha
3 weeks ago
Qiagen N.V.: Some Clarity Needed Before Buying The Dip
Qiagen N.V., a Netherlands-based medical diagnostics provider, faces market pressure due to some recent NIH funding concerns, despite strong financials and a diverse product portfolio. The company's free cash flow improved markedly in FY 2024, and the company announced a $300 million stock buyback program last month. An analysis around Qiagen N.V. follows in the paragraphs below.
Positive
The Motley Fool
3 weeks ago
2 Recent Stock Splits You've Never Heard of That Certain Wall Street Analysts Think Could Soar 39% and 62%
Stock splits can be undertaken for several reasons. They can bring a stock's price down to make it more affordable for a wider range of investors.
Neutral
Business Wire
1 month ago
QIAGEN Strengthens Global Bioinformatics Leadership With New Data Center in Australia/Asia-Pacific Region
VENLO, The Netherlands & REDWOOD CITY, Calif.--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the official opening of a new data center in Melbourne, Australia, designed to strengthen its global bioinformatics leadership position in this region of the world. This latest addition reflects QIAGEN's ongoing commitment to enhance its bioinformatics data infrastructure, enabling initiatives to broaden the reach and use of bioinformatics products in the Australia/.
Neutral
Zacks Investment Research
1 month ago
QIAGEN Q4 Earnings Miss, Stock Crashes, Margins Expand
QGEN's performance benefits from a resilient portfolio in the fourth quarter of 2024.
Neutral
Seeking Alpha
1 month ago
Qiagen N.V. (QGEN) Q4 2024 Earnings Call Transcript
Qiagen N.V. (NYSE:QGEN ) Q4 2024 Earnings Conference Call February 6, 2025 10:00 AM ET Company Participants John Gilardi – Vice President, Head of Corporate Communications and Investor Relations Thierry Bernard – Chief Executive Officer Roland Sackers – Chief Financial Officer Conference Call Participants Tycho Peterson – Jefferies Michael Ryskin – Bank of America Securities Patrick Donnelly – Citi Doug Schenkel – Wolfe Research Dan Arias – Stifel Dan Brennan – TD Cowen Matt Sykes – Goldman Sachs Casey Woodring – J.P.
Positive
Zacks Investment Research
1 month ago
Qiagen (QGEN) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Qiagen (QGEN) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Charts implemented using Lightweight Charts™